Omeros Q1 Earnings Call Highlights
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
- Who's exposed
- OMEROmeros Named
Companies named in the story.
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the briefHow this story developed
2 reports over 50 minutes-
finance.yahoo.com You're reading this Omeros Q1 Earnings Call Highlights Neutral 0
-
finance.yahoo.com Omeros Corp (OMER) Q1 2026 Earnings Call Highlights: Strong YARTEMLEA Launch and Strategic ... Strong bullish +60
Same story, other sources
How 1 other outlet framed it- marketbeat.com Omeros Q1 Earnings Call Highlights


